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In Brief
Harris et al. show that the antioxidant
glutathione (GSH) is required for cancer
initiation but not for established tumors
partly due to upregulation of the
thioredoxin (TXN) antioxidant pathway in
the latter. Consequently, blocking both
GSH and TXN pathways synergistically
inhibits tumor growth.
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http://dx.doi.org/10.1016/j.ccell.2014.11.019SUMMARYControversy over the role of antioxidants in cancer has persisted for decades. Here, we demonstrate that
synthesis of the antioxidant glutathione (GSH), driven by GCLM, is required for cancer initiation. Genetic
loss of Gclm prevents a tumor’s ability to drive malignant transformation. Intriguingly, these findings
can be replicated using an inhibitor of GSH synthesis, but only if delivered prior to cancer onset, sug-
gesting that at later stages of tumor progression GSH becomes dispensable potentially due to compen-
sation from alternative antioxidant pathways. Remarkably, combined inhibition of GSH and thioredoxin
antioxidant pathways leads to a synergistic cancer cell death in vitro and in vivo, demonstrating
the importance of these two antioxidants to tumor progression and as potential targets for therapeutic
intervention.INTRODUCTION
Reactive oxygen species (ROS) are normal byproducts of
numerous cellular processes, such asmitochondrial metabolismSignificance
Although supplementation with antioxidants has been sugges
synthesis can, in fact, be chemopreventive. Clinical trials using
to treatmalignancies have failed though, possibly due to the res
pathway. We demonstrate that sulfasalazine (SSA) and auran
clinics to treat inflammatory diseases, can be combined with
and TXN pathwaysmay be a valuable therapeutic strategy to tr
Cand protein folding (Cairns et al., 2011). At low levels, ROS act as
signaling molecules to activate proliferation and survival path-
ways (Sena and Chandel, 2012). At moderately increased levels,
ROS damage DNA and promote mutagenesis in cells (Wisemanted to prevent cancer, we show that inhibition of antioxidant
buthionine sulfoximine (BSO), which inhibits GSH synthesis,
ponse from alterative antioxidant pathways such as the TXN
ofin (AUR), inhibitors of the TXN pathway currently used in
BSO to reduce tumorigenesis. Combined inhibition of GSH
eat cancer patients and one that can be readily implemented.
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Figure 1. Gclm Is Required for Tumor Initiation
(A) Tumor-free survival of PyMT-Gclm+/+ (n = 36) and PyMT-Gclm/ (n = 19) mice.
(B) At the endpoint (day 160), all tumors from PyMT-Gclm+/+ (n = 32) and PyMT-Gclm/ (n = 32) mice were resected and weighed. Each data point represents the
combined weight of tumors from a single mouse.
(C–E) Representative images of tumor sections from PyMT-Gclm+/+ (top) and PyMT-Gclm/ (bottom) mice stained for H&E (C), Ki67 (D), and smooth muscle
actin (SMA) (E). Scale bars represent 400 mm.
(legend continued on next page)
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and Halliwell, 1996). High ROS levels, however, exert an oxida-
tive stress on the cell that can ultimately cause cell senescence
or death (Trachootham et al., 2009). To control oxidative stress,
cells generate molecules termed antioxidants that convert ROS
into benign molecules.
The most abundant antioxidant within all cells is glutathione
(GSH) (Meister, 1983). GSH is synthesized in a two-step process;
the rate limiting step is carried out by glutamate cysteine ligase
(GCL), a heterodimer of catalytic (GCLC) and modifier (GCLM)
subunits. Gene-targeted GCLC-deficient (Gclc/) mice lack
all GSH synthesis and die during embryogenesis (Dalton et al.,
2000). In contrast, Gclm/ mice have only 10%–25% of the
GSH levels of wild-type mice, but are completely viable
(McConnachie et al., 2007). AlthoughGclm/mice have greatly
reduced GSH synthesis, no overt phenotypes in relation to can-
cer have been observed.
Cancer cells arise from activation of oncogenes and/or inacti-
vation of tumor suppressors. A key hallmark of cancer cells is
unrestrained growth (Hanahan and Weinberg, 2000). Because
generation of ROS is a byproduct of cell growth, cancer cells
sustain a much higher level of ROS production compared to
normal cells (Trachootham et al., 2006). Therefore, to avoid the
detrimental effects of oxidative stress, it is believed that cancer
cells must actively upregulate multiple antioxidant systems. By
buffering ROS levels, cancer cells are able to restrict ROS within
a range that is beneficial to promote tumor progression. Recent
reports have proposed this hypothesis (DeNicola et al., 2011;
Diehn et al., 2009; Schafer et al., 2009), yet the importance of an-
tioxidants during tumor initiation and progression still remains to
be tested. Here, we examine the impact of inhibiting the GSH
antioxidant pathway on tumorigenesis.
RESULTS
The Role of GCLM in Tumorigenesis
In order to investigate the impact of GCLM on cancer, we bred
Gclm+/ mice with MMTV-PyMT mice, which develop sponta-
neous mammary tumors, to generate MMTV-PyMT;Gclm/
mice (referred to as PyMT-Gclm/ mice) (Guy et al., 1992).
PyMT-Gclm/ mice exhibited a significantly delayed mammary
tumor onset compared to control PyMT-Gclm+/+ (Figure 1A).
Disruption of Gclm also resulted in reduced mammary tumor
burden; at experimental endpoint, the total mass of tumors
isolated from PyMT-Gclm+/+ mice exceeded that from PyMT-
Gclm/micemore than 2-fold (Figure 1B). Interestingly, a partial
gene dosage effect was evident, as mammary tumor onset was
delayed in PyMT-Gclm+/ mice, but no difference was ultimately
observed in tumorburdenatendpoint (FiguresS1AandS1Bavail-
able online).Histological analysis revealed thatwhile allmammary
tumors in control mice progressed to invasive ductal carcinoma
(IDC), tumors in PyMT-Gclm/ mice showed reduced prolifera-
tion and invasive progression (Figures 1C–1F). Furthermore,
when IDC was observed in PyMT-Gclm/ mice, it was much(F) Pathological classifications of tumors from the mice in (B). DCIS, ductal carci
(G and H) Sarcomas (G) from LSL-KrasG12D/+;Trp53fl/fl Ad-Cre Gclm+/+ (n = 4) a
weighed, as were lymphomas (H) from Pten+/;Gclm+/+ (n = 6) and Pten+/;Gclm
using log-rank (Mantel-Cox) test (A) and unpaired t test (B, G, and H). ***p < 0.00
See also Figure S1.
Cmore focal in nature (data not shown).Next,weexaminedwhether
normal mammary gland development was impaired in Gclm/
mice in order to account for any differences in tumorigenesis
that could be attributed to a preexisting organ defect. No
difference in ductal outgrowth was observed between Gclm+/+
and Gclm/ mice during mammary gland maturation (Fig-
ure S1C). Additionally, no gross differences in density of mam-
mary branches were observed in Gclm/ mice (Figure S1D).
These results demonstrate that loss of Gclm impairs mammary
tumor initiation and supports that any changes in tumorigenesis
observed inGclm/mice are directly linked to cancer outgrowth
and not a preexisting defect in mammary glands.
To extend these findings beyond the context of mammary
tumorigenesis, we examined the effect of loss of Gclm in two in-
dependent mouse models of spontaneous tumor development:
LSL-KrasG12D/+;Trp53fl/fl mice that develop sarcomas upon intra-
muscular injection of adenovirus encoding the Cre recombinase
(Ad-Cre) (Kirsch et al., 2007), and Pten+/ mice, which develop
lymphomas and thymomas (Suzuki et al., 1998). In both models,
we observed a significantly reduced tumor burden in mice lack-
ing Gclm (Figures 1G, 1H, and S1E–S1G). In support of these
results, gene expression analysis shows GCLM to be upregu-
lated across multiple human tumor types and prognostic data
indicates that cancer patients with tumors having high GCLM
mRNA have a lower probability of relapse-free survival and over-
all survival (Figures S1H and S1I). Together, these results show
that depleted GSH synthesis, driven by loss of GCLM, impairs
tumor initiation and progression.
Early Inhibition of GSH Synthesis, But Not Inhibition
upon Tumor Onset, Impairs Tumorigenesis
Buthionine-[S, R]-sulfoximine (BSO) is a potent inhibitor of GSH
synthesis (Griffith andMeister, 1979) (Figure S2) and oral delivery
is an effective pharmacological model of continuous depletion of
GSH levels in vivo (Watanabe et al., 2003). In an effort to examine
whether chemical inhibition of GSH synthesis could mirror
genetic inhibition of GSH synthesis, we treated PyMT-Gclm+/+
mice with BSO. Mice were treated at two different time points:
immediately after weaning (4 weeks old; ‘‘early BSO’’), or upon
mammary tumor onset as assessed by palpation (6–12 weeks
old; ‘‘onset BSO’’). Early BSO treatment dramatically reduced
the mammary tumor burden in PyMT-Gclm+/+ mice (Figure 2A).
Histological analysis of mammary tumors resected from early
BSO mice revealed reduced proliferation and fewer instances
of invasive carcinomas (Figures 2B and 2C), replicating
the phenotype of PyMT-Gclm/ mice. Intriguingly, when BSO
was delivered upon mammary tumor onset, tumor burden was
unchanged; as was tumor histology (Figures 2A–2C). These
findings were also observed in sarcomas from the LSL-
KrasG12D/+;Trp53fl/fl Ad-Cre mice treated with BSO at early and
onset time points (Figure 2D). To examine the temporal impact
of BSO on ROS levels within the tumors, we measured the
amount of oxidized DNA product 8-hydroxy-20-deoxyguanosinenoma in situ; IDC, invasive ductal carcinoma.
nd LSL-KrasG12D/+;Trp53fl/fl Ad-Cre Gclm/ (n = 4) mice were resected and
/ (n = 8) mice. Data are represented as mean ± SEM. P values were calculated
1; **p < 0.01.
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Figure 2. BSO Treatment Prevents Tumorigenesis
(A) At endpoint, tumors from H2O controls (n = 16) and ‘‘early BSO’’ (n = 8) or ‘‘onset BSO’’ (n = 9) treated PyMT-Gclm
+/+ mice were resected and weighed.
(B and C) Representative images of sections of tumors from PyMT-Gclm+/+ mice treated with H2O (top), ‘‘early BSO’’ (middle) or ‘‘onset BSO’’ (bottom) stained
with H&E (B) and Ki67 (C). Scale bars represent 400 mm.
(D) At endpoint, tumors from H2O controls (n = 6) and ‘‘early BSO’’ (n = 5) or ‘‘onset BSO’’ (n = 4) treated LSL-Kras
G12D/+;Trp53fl/fl Ad-Cre Gclm+/+ mice were
resected and weighed.
(E) Quantification of percentage of 8OHdG staining in tumors from (A). Data are represented as mean ± SEM. P values were calculated using unpaired t test (A, D,
and E). *p < 0.05; ***p < 0.001; n.s., nonsignificant.
See also Figure S2.
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Figure 3. PyMT-Gclm–/– Cells Survive In-
hibited GSH Synthesis
(A) Primary mammary epithelial cells (pMECs) from
PyMT-Gclm+/+ and PyMT-Gclm/ mice were
analyzed for total GSH levels (n = 3).
(B) PyMT-Gclm+/+ and PyMT-Gclm/ pMECs
were cultured with or without BSO (150 mM) for the
indicated times. Cell numbers expressed relative
to the cell count on day 1 (n = 6).
(C and D) Cells from (B) were stained on day 3 for
ROS levels (CM-H2DCFDA) (C) and for apoptosis
(AnnexinV, 7-AAD) (D) (n = 3).
(E) Immunoblotting of cytoplasmic (Cyt.) and nu-
clear (Nuc.) fractions of pMECs from PyMT-
Gclm+/+ and PyMT-Gclm/ mice on day 4.
(F) Cells from (B) were harvested on day 4 and
mRNA levels of the indicated Nrf2 target genes
were determined by quantitative RT-PCR (qRT-
PCR) (n = 6). Nqo1, NAD(P) dehydrogenase,
quinone 1, Hmox1, heme oxygenase 1, Ggt1,
gamma-glutamyltransferase 1. Data are repre-
sented as mean ± SEM. P values were calculated
using unpaired t test (A, C, D, and F) and two-way
ANOVA test (B). ***p < 0.001; **p < 0.01; *p < 0.05;
n.s., nonsignificant.(8OHdG) as a readout of ROS levels in vivo. Early BSO treatment,
which reduced tumor burden, increased the amount of 8OHdG,
while onset BSO treatment, which failed to reduce tumor burden,
had no effect (Figure 2E). The increased 8OHdG staining in early
BSO-treated tumors suggests that the ROS levels have accumu-
lated to potentially produce an oxidative stress that can hinder
the growth of the tumor. These results show that while inhibition
of GSH synthesis is effective at allowing ROS levels to rise during
the stage of tumor initiation, the same strategy has no effect on
ROS levels in established tumors. This indicates that a potential
reason for failure of BSO to impact the growth of established tu-
mors is due to an alternate mechanism for depleting ROS at later
stages of tumor progression.
GSH Synthesis Is Dispensable in Gclm Null Cells
To further investigate potential GSH-independent antioxidant re-
sponses of cancers, we isolated primary mammary epithelial
cells (pMECs) from PyMT-Gclm+/+ and PyMT-Gclm/ mice.
The GCLM subunit aides GCLC in producing de novo GSH;
therefore loss of GCLM would be expected to decreaseCancer Cell 27, 211–222GSH synthesis without abolishing it
completely. Accordingly, we observed
greatly reduced, though still detectable,
GSH levels in PyMT-Gclm/ pMECs
(Figure 3A). We postulated that PyMT-
Gclm/ pMECs would be more sensitive
to cell death from BSO-mediated GSH
inhibition due to their already decreased
GSH levels. Although PyMT-Gclm/
pMECs showed a reduction in cell growth
rate, surprisingly, they were completely
resistant to the effects of BSO (Figure 3B),
suggesting that cells can compensate for
further reduced GSH synthesis. The ef-fects on cell growth corresponded with changes in both ROS
levels and cell death and treatment with the antioxidant Trolox
was able to rescue these effects (Figures 3C and 3D). To gain
molecular insight into the potential driving force behind the
response to glutathione depletion, we looked for evidence of up-
regulation of drivers of antioxidant gene expression. Nuclear fac-
tor (erythroid-derived 2)-like factor 2 (NFE2L2 or Nrf2) is a major
antioxidant transcription factor that is stabilized upon oxidative
stress; therefore we examined its levels and location in response
to Gclm deletion. Interestingly, both protein stabilization of Nrf2
within the nucleus and Nrf2 target gene mRNA levels were
increased in PyMT-Gclm/ pMECs (Figures 3E and 3F). These
results indicate that cells can survive loss of the GSH antioxidant
pathway and this may potentially be mediated through Nrf2-
dependent mechanisms.
Reduced GSH Synthesis Results in Increased Cystine
Levels in Cells
In a continued effort to define the alternative mechanism for ROS
reduction in BSO-treated cells, we examined the metabolites, February 9, 2015 ª2015 Elsevier Inc. 215
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Figure 4. Inhibition of GSH Synthesis Results in Increased Intracellular Cystine Levels
(A) Schematic representation of antioxidant buffering provided by increased cystine import upon inhibition of de novo GSH synthesis. Glu, glutamate; Cys2,
cysteine.
(B–F) Quantitative metabolomics were performed to determine GSH (B), glutamate (C), and cystine (D) levels and NADPH/NADP+ (E) and GSH/GSSG (F) ratios in
pMECs fromPyMT-Gclm+/+ andPyMT-Gclm/mice (n = 4). Data are represented asmean ± SEM. P valueswere calculated using unpaired t test (B–F). *p < 0.05;
n.s., nonsignificant.involved in the synthesis of GSH. Glutamate, one of the sub-
strates used by GCLM/GCLC to produce GSH, is required for
the cellular import of cystine. Glutamate is exported from the
cell in exchange for cystine via the amino acid transporter
system Xc-, which features the XCT subunit (also known as
SLC7A11) (Figure 4A) (Sasaki et al., 2002). Imported cystine,
once reduced to cysteine in a NADPH-dependent manner,
is incorporated into a multitude of antioxidant molecules. We
reasoned that if GSH synthesis was inhibited, the excess gluta-
mate that accumulated might be exported in exchange for the
import of cystine. Accordingly, the increased cystine levels
would be able to drive antioxidant synthesis to buffer ROS levels
when GSH was depleted. To investigate this hypothesis, PyMT-
Gclm+/+ and PyMT-Gclm/ pMECs were analyzed using quan-
titative metabolomics. In pMECs without Gclm, we observed
decreased GSH levels, but increased glutamate and cystine
levels (Figures 4B–4D). The metabolite NADPH regenerates
oxidized GSH (GSSG) and its synthesis has been linked to
oncogenic modifications and tumorigenesis (Vander Heiden
et al., 2009). Interestingly, while we observe an increase
NADPH/NADP+ levels, no difference in GSH/GSSG levels was
found (Figures 4E and 4F), suggesting that increased regenera-
tion of GSH by NADPH is not occurring and is instead possibly
used for cystine reduction. Overall, these results suggest that216 Cancer Cell 27, 211–222, February 9, 2015 ª2015 Elsevier Inc.when GSH synthesis is reduced, increased intracellular cystine
levels may drive an alternative antioxidant pathway.
Increased Expression of the TXN Antioxidant Pathway
Occurs in GSH-Depleted Cells and Tumors
Previous reports had shown that overexpression of XCT can
rescue the growth of cells that are completely deficient in
GSH production, and this rescue was highly dependent upon
the activity of the thioredoxin (TXN) antioxidant pathway (Man-
dal et al., 2010). Interestingly, mRNA of thioredoxin reductase
1 (TXNRD1) has been shown to be upregulated in the livers of
Gclm/ mice (Haque et al., 2010). The TXN pathway can effi-
ciently reduce ROS levels and be regenerated by TXNRD in a
GSH-independent manner (Holmgren and Lu, 2010). We postu-
lated that increased expression of TXN pathway components
could be facilitated by elevated cystine levels observed PyMT-
Gclm/ pMECs and could contribute to the mechanism by
which GSH-depleted cells buffer ROS. In PyMT-Gclm/
pMECs, we observed increases in the mRNA expression of
several genes that promote the TXN antioxidant pathway and
in the protein expression of Txn1 relative to PyMT-Gclm+/+
pMECs (Figures 5A and 5B). Additionally, we found that
the expression of the tumor-associated antigen CD44, which
stabilizes XCT to promote cystine import, also increased in
AC
**
D E
B
PyMT-Gclm+/+ 
PyMT-Gclm-/- 
Xc
t
Cd
44
Tx
n1
Tx
nrd
1
0.0
0.5
1.0
1.5
2.0
2.5
**
** **
Txn1
Actin
No
rm
al
Tu
mo
r-6
-4
-2
0
2
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
-3
-2
-1
0
1
2
-4
-2
0
2
*** *** ***
m
R
N
A
[fo
ld
 c
ha
ng
e 
re
la
tiv
e 
to
 rp
s9
]
PyMT
Gclm+/+
PyMT
Gclm-/-
No
rm
al
Tu
mo
r
No
rm
al
Tu
mo
r
Figure 5. GSH-Depleted Cells and Tumors Upregulate the TXN Antioxidant Pathway
(A) pMECs from PyMT-Gclm+/+ and PyMT-Gclm/ mice were harvested and mRNA levels of the indicated genes were determined by qRT-PCR (n = 6).
(B) Immunoblotting of total lysate of pMECs from PyMT-Gclm+/+ and PyMT-Gclm/ mice.
(C–E) The mRNA levels of XCT, TXN1, and TXNRD1 in the TCGA invasive breast carcinoma data set. Data are represented as mean ± SEM (A) and box and
whiskers plots (C–E) with box defining 25th percentile (lower quartile), median and 75th percentile (upper quartile) and whiskers defining maximum and minimum
values. P values were calculated using unpaired t test (A) Mann-Whitney U test (C–E). ***p < 0.001; **p < 0.01.
See also Figure S3.PyMT-Gclm/ pMECs (Figure 5A) (Ishimoto et al., 2011).
In addition, we found that deletion of Gclm in mouse embry-
onic fibroblasts (MEF) and sarcomas from Gclm/ LSL-
KrasG12D/+;Trp53fl/fl Ad-Cre mice upregulated TXN pathway-
related gene expression, indicating that this effect is not limited
to the mammary system (Figure S3). We hypothesized that if the
TXN antioxidant pathway is upregulated in cancer cells
compared to normal cells, this may help prime the tumor to
survive GSH depletion. Indeed, examination of ‘‘The Cancer
Genome Atlas’’ (TCGA) breast cancer data set revealed XCT,
TXN1, and TXNRD1 to be upregulated in breast cancer patient
tissue compared to normal tissue (Figures 5C–5E) (Cancer
Genome Atlas Network, 2012). These results suggest that the
TXN pathway may compensate for inhibition of the GSH antiox-
idant pathway, and this alternative antioxidant pathway is
elevated in established malignant tumors.
GSH and TXN Antioxidant Pathways Synergistically
Support Cancer Cell Survival
In order to interrogate the reliance of cancer cells on the TXN
antioxidant pathway when GSH synthesis was reduced, we uti-Clized the chemical inhibitors sulfasalazine (SSA), which blocks
the XCT transporter subunit and reduces cystine uptake (Gout
et al., 2001), and auranofin (AUR), which reduces regeneration
of TXN by inhibiting TXNRD (Marzano et al., 2007) (Figure 6A).
Validation of both inhibitors showed robust and specific inhibi-
tion of the targeted pathways (Figures S4A–S4E). We chose to
study the rapidly proliferating breast cancer cell line MDA-MB-
231 to examine the coreliance on GSH and TXN antioxidant
pathways in malignant cells. Treatment of cancer cells with
BSO induced an increase in cystine uptake, identical to that
observed with knockdown of GCLM (Figure 6B). While treat-
ment with BSO, SSA, or AUR alone had minimal or no effect
on the survival of cancer cells, combination of BSO with either
SSA or AUR induced striking increases in cell death (Figures
6C and 6D). Cells depleted simultaneously of GCLM and TXN
mRNA displayed reduced growth that matched chemical
inhibition with BSO and SSA; they were also resistant to
further growth inhibition by the chemicals (Figures S4F and
S4G). Furthermore, the observed effects were dependent on
increased ROS, as addition of Trolox or the antioxidant N-acetyl
cysteine (NAC) was able to rescue the synergistic cell deathancer Cell 27, 211–222, February 9, 2015 ª2015 Elsevier Inc. 217
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Figure 6. GSH and TXN Antioxidant Path-
ways Act in Synergy in Cancer Cells
(A) Schematic representation of target inhibition by
BSO, SSA, and AUR.
(B) 14C-Cystine uptake assay was performed
on MDA-MB-231 cells expressing shControl or
shGCLM and not treated (NT) or treated with BSO
(150 mM), SSA (250 mM), or both (n = 3).
(C) MDA-MB-231 cells were not treated (NT) or
treated with BSO (150 mM), SSA (250 mM), or AUR
(250 nM) alone or in the indicated combinations
and cultured for indicated times. Cell numbers are
expressed relative to cell count on day 1 (n = 3).
(D) Cells from (C) were analyzed on day 3 for
apoptosis.
(E and F) ROS levels (E) and cell numbers (F) of
MDA-MB-231 cells not treated (NT) or treated with
BSO (150 mM), SSA (250 mM), AUR (250 nM), Trolox
(250 mM), or NAC (1 mM) alone or in the indicated
combinations and cultured for indicated times. ROS
levels (E) weremeasured on day 2. Cell numbers are
expressed relative to cell count on day 1 (n = 3).
Data are represented as mean ± SEM. P values
were calculated using unpaired t test (B, D, and E)
and two-way ANOVA test (C and F). ***p < 0.001;
**p < 0.01; *p < 0.05; n.s., nonsignificant.
See also Figure S4.induced by BSO plus SSA or AUR (Figures 6E and 6F). Addition-
ally, we observed similar phenotypes when examining cell lines
from multiple different cancer types including lymphoma, glio-
blastoma, and nonsmall cell lung carcinoma (Figures S4H and
S4I), suggesting that these in vitro findings were not limited to
breast cancer cells. To investigate whether the GSH and TXN
pathways synergize in vivo, we injected mice with MDA-MB-
231 breast cancer cells and treated them with BSO, SSA, or
both agents. While no effect on tumor growth was observed
with administration of single agents, combined delivery of
BSO and SSA synergistically reduced tumor growth in vivo (Fig-
ures 7A, 7B, and S5A). Corresponding results were found
testing xenograft models using chemo-resistant patient-derived
xenograft (PDX) and HCT116 colon cancer cells (Figures 7C,
7D, and S5B); again indicating that these findings may extend
to other cancer types. Finally, cancer cells with combined
depletion of GCLM and TXN mRNA showed reduced tumor
burden in vivo that was matched and was not further exacer-
bated by treatment with BSO and SSA (Figures 7E and S5C).
These results suggest that both GSH and TXN antioxidant
pathways manage ROS levels in malignant tumors and, thus,218 Cancer Cell 27, 211–222, February 9, 2015 ª2015 Elsevier Inc.combined inhibition of both pathways is
required for effective induction of cancer
cell death (Figure 8).
DISCUSSION
The role of antioxidants in tumorigenesis
has been controversial for years. An over-
load of ROS within the cell leads to death,
and the idea of inhibiting antioxidant path-
ways in order to kill cancer cells was firstconceived long ago (Arrick et al., 1983). The concept that ROS
can promote de novo mutagenesis arose almost concurrently
and many believed that antioxidants could prevent or inhibit
tumorigenic changes in preneoplastic cells (Bandy and Davison,
1990). Furthermore, later studies showed that ROS can mediate
the activation of multiple signaling cascades that promote prolif-
eration (Sena and Chandel, 2012). Activation of oncogenic path-
ways leads to increased production of ROS through numerous
mechanisms (Cairns et al., 2011). The subsequent oxidative
stress produced can promote signaling events, DNA damage,
and mutagenesis and become a tumor promoter. If, however,
this oxidative stress is not controlled, it can accumulate to higher
levels that cause senescence or apoptosis and thus turn into
a tumor suppressor. Recently, there has been a resurgence of
evidence indicating that antioxidants contribute to tumorigen-
esis by preventing ROS accumulation and subsequent oxidative
stress in cancer cells (DeNicola et al., 2011; Diehn et al., 2009;
Schafer et al., 2009). Our results show that antioxidants, such
as GSH, are required for cancer initiation and suggest that
reduced antioxidant activity can in fact be chemopreventive.
These findings are consistent with significantly increased cancer
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Figure 7. Combined Inhibition of GSH and
TXN Antioxidant Pathways Synergistically
Induces Cancer Cell Death In Vivo
(A) Tumor volume of SCID mice (n = 8/group) in-
jected with MDA-MB-231 cells into the #4 fat pad
and treated with H2O, BSO, SSA, or BSO + SSA
was monitored from initiation of drug treatment
until endpoint (day 12).
(B) Tumors resected from mice in (A) at the end
point were weighed.
(C) Tumor volume of SCID mice with subcutane-
ous transplantation of PDX treated with H2O (n =
3), BSO (n = 5), SSA (n = 4), and BSO+SSA (n = 5)
was monitored from initiation of drug treatment
until endpoint (day 12).
(D) NIH III mice (n = 5/group) with hind flank in-
jections of HCT116 cells were treated with H2O,
BSO, SSA, or BSO+SSA. At endpoint, each tumor
was resected from each animal and tumor mass
was determined.
(E) NIH III mice (n = 10/group) with hind flank
injections of HCT116 cells expressing shControl
or shGCLM and shTXN and treated with H2O or
BSO+SSA. At endpoint, each tumor was resected
from each animal and tumor mass was deter-
mined. Data are represented as mean ± SEM.
p values were calculated using two-way ANOVA
test (A and C) and unpaired t test (B, D, and E).
***p < 0.001; **p < 0.01; *p < 0.05; n.s.,
nonsignificant.
See also Figure S5.incidences observed in clinical trials that investigated whether
antioxidants could prevent cancer (Klein et al., 2011; Omenn
et al., 1996). These together suggest that not only caution should
be exercised when using dietary antioxidant supplementation
but also enzymes in antioxidant pathways may be legitimate
targets for chemoprevention and cancer therapeutics (Gorrini
et al., 2013).
Intriguingly, inhibition of the GSH pathway in an established
malignant tumor did not significantly impede its progression.
We hypothesize that reduction of ROS levels, in the presence
of inhibited GSH synthesis, can specifically arise from the
TXN antioxidant pathway due to increased cystine import,
along with the increased expression of genes in this pathway
found in malignant tumors. We postulate that the TXN antioxi-
dant pathway can also be driven by the oncogenic transcription
factor Nrf2, but further studies are required to validate this
hypothesis. While our preliminary analysis focused on Nrf2,
rescue for depleted antioxidants may also occur from
other sources, such as p53, ATF, and FOXO families of tran-
scription factors (Gutie´rrez-Uzquiza et al., 2012; NogueiraCancer Cell 27, 211–222et al., 2008; Rufini et al., 2012; Vousden
and Ryan, 2009). Furthermore, although
the study investigated the TXN antioxi-
dant pathway, we cannot rule out that
the increased cystine uptake that occurs
in cells with reduced GSH synthesis may
be diverted to other antioxidant path-
ways. A comprehensive examination of
the mechanisms of antioxidant pathways
in cancer cells would yield great insighttoward understanding how interconnected antioxidant re-
sponses might support tumorigenesis.
GSH is the most abundant antioxidant in the cell, yet clinical
trials targeted at inhibiting GSH synthesis alone have been met
with little success (Bailey et al., 1997). Here, we demonstrate
the capacity of cancer cells to survive a decrease in GSH synthe-
sis by using the TXN antioxidant pathway to buffer ROS levels.
This response is similar to that seen in oncogenic signaling path-
ways, such as when tumors become resistant to targeted thera-
pies (Muranen et al., 2012). Combination therapy inhibiting both
GSH and TXN antioxidant pathways may yield success when
applied in the clinical setting. Interestingly, both SSA and AUR,
which act synergistically with BSO to induce cancer cell death,
are disease-modifying antirheumatic drugs (DMARDs) currently
being used to treat inflammatory diseases (Mo¨tto¨nen et al.,
1999); this underscores the realistic and potentially rapid clinical
application of these findings. Further insight into the roles of
other antioxidants, and how they act both alone and together,
will no doubt provide important clues into more effective treat-
ments for cancer patients., February 9, 2015 ª2015 Elsevier Inc. 219
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Figure 8. Treatment Strategies Involving Blockade of GSH and TXN
Antioxidant Pathways in Malignant Tumors
Inhibition of GSH synthesis, through treatment with BSO, inhibits cancer
initiation. If malignant transformation has already occurred, upregulation of
alternative antioxidant pathways, including the TXNpathway, render treatment
with BSO alone ineffective. Inhibition of both GSH and TXN pathways with
combined delivery of BSO and SSA and/or AUR synergistically induces cancer
cell death in established tumors.EXPERIMENTAL PROCEDURES
Murine Tumor Models and Tumor Xenografts
MMTV-PyMT, LSL-KrasG12D/+; Trp53fl/fl, Pten+/, and Gclm/ mice were
generated as previously described (Guy et al., 1992; Kirsch et al., 2007;
McConnachie et al., 2007; Suzuki et al., 1998) and kept on the identical genetic
background. PyMT-Gclm+/+ and PyMT-Gclm/ mice (C57B6 background)
were monitored weekly for palpable tumors, commencing at an age of
60 days. The experimental endpoint was defined as 160 days of age or if a
humane endpoint was reached. At endpoint, all tumors from each individual
mouse were resected and weighed. Data points represent a combined weight
of tumors from a single mouse. Samples were divided in half, with one half
being snap frozen at 80C and the other half being fixed in 10% buffered
formalin for use in histological analyses. Similar procedures were conducted
for LSL-KrasG12D/+;Trp53fl/fl Ad-Cre Gclm+/+ and LSL-KrasG12D/+;Trp53fl/fl
Ad-Cre Gclm/ mice (8 weeks after Ad-Cre injection in skeletal muscle)
and Pten+/;Gclm+/+ and Pten+/;Gclm/ mice (6 months of age). MMTV-
PyMTmice (129 background) were used for experiments involving continuous
oral delivery of BSO (20 mM) and were performed as previously described
(Watanabe et al., 2003). The experimental endpoint was 120 days of age or
earlier if a humane endpoint was reached. Endpoints are earlier than in
MMTV-PyMT-C57B6 mice because the former animals develop tumors
sooner. At endpoint, all tumors from each individual mouse were resected,
weighed and divided into two samples for further analysis as described above.
Data points represent a combined weight of tumors from a single mouse.
Similar procedures were conducted for LSL-KrasG12D/+;Trp53fl/fl Ad-Cre220 Cancer Cell 27, 211–222, February 9, 2015 ª2015 Elsevier Inc.mice. Severe combined immunodeficiency (SCID) mice (n = 8/group) were in-
jected into their #4 fat pads with 1 3 106 MDA-MB-231 cells in PBS with Ma-
trigel. Mice were divided into four treatment cohorts: H2O, untreated drinking
water with daily intraperitoneal (i.p.) injection of vehicle control (0.9% NaCl so-
lution); BSO, 20 mM BSO-treated drinking water with daily i.p. injection of
vehicle control (0.9% NaCl solution); SSA, untreated drinking water with daily
i.p. injection of SSA (250mg/kg); BSO +SSA, 20mMBSO-treated drinkingwa-
ter with daily i.p. injection of SSA (250 mg/kg). Tumor volumes were measured
every 3 days until endpoint (day 12). At endpoint, tumors were excised,
weighed, and processed for further analysis as described above. SCID mice
(3–5/group) were subcutaneously transplanted with tumor fragments (2–
3 mm) from a PDX model and then treated as previously mentioned with
BSO and SSA. NIH III mice (n = 5–10/group) were subcutaneously injected
with 1 3 106 HCT116 cancer cells (parental, shControl, or shGCLM+shTXN)
and then treated as previously mentioned with BSO and SSA. The Institutional
Animal Care and Use Committee (IACUC) of the University Health Network
(UHN) approved all animal procedures. Animals were housed in the UHN An-
imal Resource Centre (fully accredited by the Canadian Council for Animal
Care). The PDX model was generated from tumor tissue obtained from a con-
senting patient under a research protocol approved by the UHN Research
Ethics Board (UHN REB#06-0196-CE).
Cells and Reagents
Isolation of pMECs was performed as previously described (Joshi et al.,
2010). Each data point for experiments involving pMECs refer cells isolated
from at least three separate mice and cultured separately. All pMECs were
cultured for only one passage and maintained at 3% oxygen and in serum-
free medium. Isolation of MEFs was performed as previously described (Inoue
et al., 2013). All cancer cell lines were obtained from ATCC and cultured as
specified. All reagents were obtained from Sigma-Aldrich, except for Trolox
(Millipore).
Histology, Immunohistochemistry, and Pathological Analysis
Formalin-fixed tumor samples were processed and embedded in paraffin.
Tissue sections (5 mm) were deparaffinized and stained with hematoxylin
and eosin (H&E), Ki67, anti-smooth muscle actin antibody (Dako; M0851) or
anti-8 hydroxyguanosine antibody [15A3] (Abcam; ab62623). Tumor slides
stained for H&E and SMA, blinded and were evaluated by light microscopy
and scored by two independent pathologists (S.J.D. and A.A.).
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and five figures and can be found with this article online at http://dx.doi.org/
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